{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T01:19:22Z","timestamp":1775783962668,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urology"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.urology.2007.07.017","type":"journal-article","created":{"date-parts":[[2007,12,28]],"date-time":"2007-12-28T15:51:33Z","timestamp":1198857093000},"page":"1075-1078","source":"Crossref","is-referenced-by-count":37,"title":["The Safety and Efficacy of Different Doses of Bacillus Calmette Gu\u00e9rin in Superficial Bladder Transitional Cell Carcinoma"],"prefix":"10.1016","volume":"70","author":[{"given":"Madhu S.","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moneet","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumit","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayank","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Lavania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitendra","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2007.07.017_bib1","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/S0022-5347(01)65396-5","article-title":"A combined analysis of European Organization for Research and Treatment of Cancer and Medical Research Council randomized trials for the prophylactic treatment of stage TaT1 bladder cancer","volume":"156","author":"Pawinski","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2007.07.017_bib2","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/S0022-5347(01)67427-5","article-title":"Apparent failure of current intravesical chemotherapy prophylaxis to influence the long term course of superficial transitional cell carcinoma of the bladder","volume":"153","author":"Lamm","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2007.07.017_bib3","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0094-0143(21)00424-9","article-title":"Long-term results of intravesical therapy for superficial bladder cancer","volume":"19","author":"Lamm","year":"1992","journal-title":"Urol Clin N Am"},{"key":"10.1016\/j.urology.2007.07.017_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00184040","article-title":"Strategy for improving therapy of superficial bladder cancer","volume":"9","author":"Ratliff","year":"1991","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2007.07.017_bib5","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/0952-7915(93)90128-F","article-title":"Non-antibody immunotherapy of cancer","volume":"5","author":"Chapman","year":"1993","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.urology.2007.07.017_bib6","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1464-410X.1987.tb05039.x","article-title":"Local immune responses after intravesical BCG treatment for carcinoma in situ","volume":"60","author":"El-Demiry","year":"1987","journal-title":"Br J Urol"},{"key":"10.1016\/j.urology.2007.07.017_bib7","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/S0022-5347(17)37668-1","article-title":"Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall","volume":"147","author":"Prescott","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2007.07.017_bib8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-5347(17)39366-7","article-title":"Elevations of cytokines interleukin-1, interleukin-2, and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy","volume":"144","author":"Bohle","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2007.07.017_bib9","series-title":"BCG in Superficial Bladder Cancer","first-page":"11","article-title":"Aspects of non-specific immunotherapy with BCG in superficial bladder cancer: an overview","author":"Van der Meijden","year":"1989"},{"key":"10.1016\/j.urology.2007.07.017_bib10","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","article-title":"A randomized trial of intravesical doxorubicin and intravesical bacille Calmette-Gu\u00e9rin for transitional cell carcinoma of the bladder","volume":"325","author":"Lamm","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2007.07.017_bib11","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0022-5347(17)40002-4","article-title":"Bacillus Calmette-Gu\u00e9rin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer","volume":"143","author":"Martinez-Pifieiro","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2007.07.017_bib12","series-title":"BCG in Superficial Bladder Cancer","first-page":"285","article-title":"BCG RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer: rationale and design of the trial of the Southeast Co-Operative Urological Group, The Netherlands","author":"Van der Meijden","year":"1989"},{"key":"10.1016\/j.urology.2007.07.017_bib13","first-page":"301A","article-title":"Improvement in the use of BCG for superficial bladder cancer","volume":"139","author":"Morales","year":"1989","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2007.07.017_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0022-5347(17)37707-8","article-title":"A low dose bacillus Calmette-Gu\u00e9rin regimen in superficial bladder cancer therapy: is it effective?","volume":"146","author":"Pagano","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2007.07.017_bib15","series-title":"BCG in Superficial Bladder Cancer","first-page":"271","article-title":"Mitomycin C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer","author":"Rintala","year":"1989"},{"key":"10.1016\/j.urology.2007.07.017_bib16","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(61)90304-X","article-title":"Thiotepa in the treatment of tumours of the bladder","volume":"2","author":"Jone","year":"1961","journal-title":"Lancet"},{"key":"10.1016\/j.urology.2007.07.017_bib17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","article-title":"BCG Immunotherapy of superficial bladder cancer","volume":"124","author":"Lamm","year":"1980","journal-title":"J Urol"},{"issue":"suppl 1","key":"10.1016\/j.urology.2007.07.017_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000475204","article-title":"Improving the efficacy of BCG immunotherapy by dose reduction","volume":"27","author":"Pagano","year":"1995","journal-title":"Eur Urol"},{"issue":"suppl 1","key":"10.1016\/j.urology.2007.07.017_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000475203","article-title":"Improving the safety of BCG immunotherapy by dose reduction","volume":"27","author":"Martinez-Pinerio","year":"1995","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2007.07.017_bib20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00005392-200102000-00011","article-title":"The ablative effect of quarter dose bacillus Calmette-Gu\u00e9rin on a papillary marker lesion of the bladder","volume":"165","author":"Mack","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2007.07.017_bib21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2007.07.017_bib22","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2007.07.017_bib23","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacilli Calmette-Gu\u00e9rin with a reduced dose of 27 mg in superficial bladder cancer","volume":"89","author":"Martinez-Pinerio","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2007.07.017_bib24","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0022-5347(05)68555-2","article-title":"Sequential BCG and epirubicin vs. BCG alone for superficial bladder cancers, a randomized prospective study","volume":"162","author":"Ali-el-dein","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2007.07.017_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0090-4295(92)90530-A","article-title":"BCG vs. mitomycin C intravesical therapy in superficial bladder cancers","volume":"40","author":"Debruyne","year":"1992","journal-title":"Urology"},{"key":"10.1016\/j.urology.2007.07.017_bib26","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.1016\/j.vaccine.2006.04.037","article-title":"Immunogenicity of Danish-SSI 1331 BCG vaccine in the UK: comparison with Glaxo-Evans 1077 BCG vaccine","volume":"24","author":"Gorak-Stolinska","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.urology.2007.07.017_bib27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF00299720","article-title":"Cytostatic effect of different strains of Bacillus Calmette-Gu\u00e9rin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha","volume":"20","author":"Rajala","year":"1992","journal-title":"Urol Res"},{"key":"10.1016\/j.urology.2007.07.017_bib28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4103\/0970-1591.29117","article-title":"A randomized trial comparing low dose (40 or 80 mg) with standard dose (120 mg) of bacillus Calmette-Gu\u00e9rin for superficial bladder cancer","volume":"22","author":"Vijjan","year":"2006","journal-title":"Indian J Urol"},{"key":"10.1016\/j.urology.2007.07.017_bib29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ucl.2005.01.003","article-title":"Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer","volume":"32","author":"O\u2019Donnell","year":"2005","journal-title":"Urol Clin N Am"},{"key":"10.1016\/j.urology.2007.07.017_bib30","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S0022-5347(01)64936-X","article-title":"Does isoniazid reduce side effects of intravesical bacillus Calmette-Gu\u00e9rin therapy in superficial bladder cancer?","volume":"157","author":"Vegt","year":"1997","journal-title":"J Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429507018316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429507018316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T10:42:26Z","timestamp":1630406546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429507018316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S0090429507018316"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2007.07.017","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}